

Pharmacist Evaluation of QT Prolongation Risk and Recommendation

Patient Information					Prescriber Information		
Name	Sex	M	F	DOB	Name	CSPO	
Address	Phone				Phone	Fax	
Other Relevant Information					Date/Time of Communication		
Current Medications that Prolong the QT Interval ^{1,2}							
Medication	Dose/Frequency/Duration of therapy				Indication	Degree of prolongation	
Patient-Specific Risk Factors for QT				Pharmacist's Recommendations and Comments			
Risk Factor(s) *check if applicable				Pharmacist Commentary on Applicable Risk Factors			
QTc Interval > 500 ms Advanced age (>65 years old) Female Sex Acute myocardial infarction Hypokalemia (<3.5 mmol/L) Hypomagnesemia (<0.7 mmol/L) Hypocalcemia (<1.1 mmol/L [ionized]) Bradycardia (<60 bpm) Treatment with diuretics Concurrent administration of > 1 QT interval-prolonging drugs Elevated plasma concentrations of QT interval-prolonging drugs <ul style="list-style-type: none"> Dose adjustment needed for renally-eliminated drug in patients with acute kidney injury or CKD Drug Interaction(s) Possible genetic predisposition/genetic susceptibility				Pharmacist Recommendation Baseline electrolytes (potassium, magnesium, calcium) Baseline ECG Other (specify below):			
				Pharmacist Signature:			
Physician Response and Comments							
Rejected Approved Physician Signature: _____ Date: _____							
Pharmacy Information							
Name				Phone		Fax	
Practice Setting Community Hospital LTC Other: _____				Other			

References:

1. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention, and management. Can Pharm (Ott) 2016; 149: 1 – 14.
2. Woosley RL, Romero KA. Welcome to CredibleMeds. Available: www.crediblemeds.org